 Otonomy, Inc. OTIC, a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided an update on its product pipeline and the timeline to results for the companys three ongoing clinical trials, including the Phase 3 trial of OTIVIDEX in Ménières disease. We have been able to mitigate the impact of the COVID-19 pandemic on our clinical trials by taking steps to ensure the integrity of data collection from enrolled patients and supporting the increasing number of sites able to reinitiate recruitment of new patients, said David A. Weber, Ph.D., president and CEO of Otonomy. 